Thermo Fisher Scientific
In Brief This Week: PerkinElmer, Chembio, Becton Dickinson, Fulgent Genetics, and More
News items for the in vitro diagnostic industry for the week of Sept. 20, 2021.
IVDÂ company executives noted that the acceptance and acceleration of decentralized care models have increased, enabling more effective testing for many conditions.
Thermo Fisher Scientific Expects 12 Percent Revenue Growth in 2022
The guidance for next year assumes, among other things, $6.0 billion in revenue from clinical research services provider PPD, which Thermo Fisher is set to acquire this year.
Thermo Fisher Scientific Receives CE Mark for TaqPath COVID-19 RNase P 2.0 Testing Kit
The assay, which received FDA Emergency Use Authorization in July, is designed to compensate for current and future COVID-19 viral mutations.
FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC
This is the first time the FDA has approved a drug specifically for NSCLC patients who harbor rare EGFR Exon20 insertion mutations.
Jul 28, 2021
Thermo Fisher Scientific Q2 Revenues up 34 Percent
Apr 29, 2021